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Vaccination to reduce 
antimicrobial resistance
With the pipeline of new antibiotics 
running dry, vaccines are being 
proposed as a key part of the toolkit 
used to fight antimicrobial resistance.1 
Amy Ginsburg and Keith Klugman 
(November 2017, e1176–77)2 suggest 
that a reduction in resistant pathogens 
might be easier to achieve in many 
countries via vaccines than through 
other interventions, such as improved 
hygiene and sanitation. However, 
vaccines are rarely designed to target 
resistant pathogens directly, with the 
notable exception of pneumococcal 
conjugate vaccines (PCVs) that protect 
against serotypes of Streptococcus 
pneumoniae displaying high resistance 
frequency. Hence, vaccines’ effect 
of reducing antimicrobial resistance 
has been mostly regarded as a highly 
desirable byproduct. The scale of the 
problem of antimicrobial resistance 
now requires us to formally integrate 
the effect of vaccines on antimicrobial 
resistance into decision-making in 
public health.
Vaccines, arguably more than any 
other public health intervention, are 
subject to rigorous evaluations before 
integration into national immunisation 
programmes. Because of the non-
linear effects of transmission-reducing 
vaccines, embedding mathematical 
modelling forecasts in economic 
evaluations is the gold standard for 
impact predictions.3 Similarly, the 
interplay between vaccination and the 
emergence and spread of antimicrobial 
resistance will probably yield complex 
dynamics that require mathematical 
modelling analysis. The characteristics 
and efficacy of a particular vaccine will 
influence the linked direct and indirect 
reductions in resistance burden and 
antibiotic use.4,5 Meanwhile, vaccines 
against non-focal pathogens (ie, 
pathogens which themselves are 
not the targets of resistance control) 
might have similar and substantial 
benefits.4,5 However, there is a scarcity of 
modelling studies that aim to quantify 
the public health effect of vaccines on 
antimicrobial resistance. Furthermore, 
none of these models have integrated 
an economic framework.4
Mathematical models have been 
able to reflect both the fall of penicillin-
resistant S pneumoniae and the 
subsequent rise in resistance in non-
vaccine serotypes after the introduction 
of PCVs.6 Notwithstanding these post-
hoc studies, developing mechanistic 
models that show the empirical relation 
between an antibiotic’s use and the 
rising frequency of resistance against 
the antibiotic has been challenging.7–9 
Without an accurate quantification 
of the selection mechanisms through 
which resistance frequency is main-
tained, it will be impossible to base 
policy decisions on model forecasts.
To couple vaccine programmes 
with an evidence-based strategy for 
antimicrobial resistance, we must now 
move from blanket recommendations 
of vaccine use for antimicrobial 
resistance control to a vaccine-specific, 
pathogen-specific, and setting-specific 
quantification of vaccine policy. 
This crucial shift will rely on a new 
generation of mathematical models 
and of the economic frameworks in 
which these models will be embedded.
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